Fevzi BEDİR, Hüseyin KOCATÜRK, Mehmet Sefa ALTAY, Engin ŞEBİN, Banu BEDİR

Serum paraoxonase 1 and 3 activities in benign and malignant diseases of the prostate and changes in levels following robotic-assisted laparoscopic radical prostatectomy

Background/aim: This study aimed to examine serum paraoxonase 1 and 3 (PON1 and PON3) activities in benign and malignant diseases of the prostate, to determine lipid profile and malondialdehyde (MDA) levels, and to investigate changes in levels following robotic-assisted laparoscopic radical prostatectomy (RALRP). Materials and methods: A total of 137 patients, including a control group, were enrolled in the study and assigned into four groups. Group 1 (n = 33) consisted of patients previously undergoing RALRP with no recurrence, group 2 (n = 36) consisted of patients diagnosed with prostate cancer (PCa) and undergoing RALRP, and group 3 (n = 34) consisted of patients diagnosed with benign prostatic hyperplasia. The control group (n = 34) consisted of healthy individuals. Serum low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride, cholesterol, prostate-specific antigen (PSA), PON1, PON3, and MDA values were measured. In addition, group 2 MDA, PON1, PON3, and PON1/HDL levels were investigated preoperatively and at the first month postoperatively. Results: Significant changes were found in PON1, PON3, and MDA levels. PON1 and PON3 levels decreased significantly in patients with PCa, while MDA levels increased. PON1 and PON3 increased postoperatively in the PCa group, while MDA decreased. BPH group PON1, PON3, and MDA levels were higher than those of the control group. Conclusion: An increase in free oxygen radicals in the body or a decrease in endogenous antioxidant enzyme levels can result in malignant and benign diseases of the prostate. Surgical excision of malignant tissue in PCa causes a decrease in oxidative stress.

PDF

___

1. Şenel C, Tuncel A. Prostat Kanseri Belirteçleri. Türkiye Klinikleri Urology-Special Topics, 2017;10 (2): 93-101 (in Turkish).
2. Rawla P. Epidemiology of Prostate Cancer. World Journal of Oncology. 2019; 10 (2): 63-89. doi:10.14740/wjon1191
3. De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology. 1999; 53 (3): 29-40.
4. Zhang S, Li LH, Qiao HM, Yang X, Chen L et al. Regulation of the antioxidant response by MyoD transcriptional coactivator in castration-resistant prostate cancer cells. Urology. 2019; 123 (296): (9-18). doi:10.1016/j.urology.2018.04.028
5. Kaya E, Ozgok Y, Zor M, Eken A, Bedir S et al. Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study. Advances In Clinical And Experimental Medicine 2017; 26 (7): 1095-1099. doi:10.17219/ acem/66837
6. Babior BM. Phagocytes and oxidative stress. American Journal Medicine 2000; 109 (1): 33-44. doi:10.1016/s0002- 9343(00)00481-2
7. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutrition Metabolism Cardiovascular Diseases 2005; 15 (4): 316-328. doi:10.1016/j.numecd.2005.05.003
8. Cobanoglu U, Demir H, Duran M, Şehitogullari A, Mergan D et al. Erythrocyte catalase and carbonic anhydrase activities in lung cancer. Asian Pacific Journal of Cancer Prevention 2010; 11 (5): 1377-1382
9. Ng CJ, Shih DM, Hama SY, Villa N, Navab M et al. The paraoxonase gene family and atherosclerosis. Free radical Biology & Medicine. 2005; 38 (2): 153-163. doi:10.1016/j. freeradbiomed.2004.09.035
10. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arteriosclerosis, Thrombosis, and Vascular Biology 2001; 21 (4): 542-547. doi:10.1161/01.atv.21.4.542
11. Sinha K, Das J, Pal PB, Sil PC. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Archives of Toxicology 2013; 87 (7): 1157-1180. doi:10.1007/s00204-013-1034-4
12. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Letters 2009; 282 (2): 125- 1236. doi:10.1016/j.canlet.2008.12.011
13. Precourt LP, Amre D, Denis MC, Lavoie JC, Delvin E et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011; 214 (1): 20-36. doi:10.1016/j. atherosclerosis.2010.08.076
14. Gomaraschi M, Calabresi L, Franceschini G. High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease. Expert Opinion On Therapeutic Targets 2006; 10 (4): 561-572. doi:10.1517/14728222.10.4.561
15. Zamanian-Daryoush M, DiDonato JA. Apolipoprotein A-I and Cancer. Frontier Pharmacology 2015; 6: 265. doi:10.3389/ fphar.2015.00265
16. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. Journal of the American College of Cardiology 2010; 55 (25): 2846- 2854. doi:10.1016/j.jacc.2009.12.069
17. Yang C, Tian G, Mi J, Wei X, Li X et al. Causal relevance of circulating high-density lipoprotein cholesterol with cancer: a Mendelian randomization meta-analysis. Scientific Reports 2015; 5: 9495. doi:10.1038/srep09495
18. Bull CJ, Bonilla C, Holly JM, Perks CM, Davies N et al. Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Medicine 2016; 5 (6): 1125-1136. doi:10.1002/ cam4.695
19. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metabolism and Disposition 1991; 19 (1): 100-106
20. Eroglu M, Yilmaz N, Yalcinkaya S, Ay N, Aydin O et al. Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients. The Kaohsiung Journal of Medical Sciences. 2013; 29 (7): 368-373. doi:10.1016/j. kjms.2012.11.004
21. Arenas M, Rodriguez E, Sahebkar A, Shaygani H, Gohari G. Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis. Critical Reviews In Oncology/Hematology. 2018; 127: 6-14. doi:10.1016/j. critrevonc.2018.04.005
22. Mahrooz A, Zargari M, Sedighi O, Shaygani H, Gohari G. Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis. Clinical and investigative Medicine Medecine Clinique Et Experimentale. 2012; 35 (3): 144-151. doi:10.25011/cim.v35i3.16590
23. De la Iglesia R, Mansego ML, Sanchez-Muniz FJ, Zulet MA, Martinez JA. Arylesterase activity is associated with antioxidant intake and paraoxonase-1 (PON1) gene methylation in metabolic syndrome patients following an energy restricted diet. Experimental and Clinical Science Journal 2014; 13: 416- 426.
24. Jayakumari N, Thejaseebai G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. Journal of Clinical Biochemistry and Nutrition 2009; 45 (3): 278-84. doi:10.3164/jcbn.08-255
25. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. The Journal of Biological Chemistry 2000; 275 (43): 33435-33442. doi:10.1074/jbc. M004543200
26. Furlong CE, Marsillach J, Jarvik GP, Costa LG. Paraoxonases-1, -2 and -3: What are their functions? Chemico-biological Interactions. 2016; 259: 51-62. doi:10.1016/j.cbi.2016.05.036
27. Schweikert EM, Devarajan A, Witte I, Abou-Elnoeman SE. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death and Differentiation. 2012; 19 (9): 1549-1560. doi:10.1038/ cdd.2012.35
28. Merendino RA, Salvo F, Saija A, Aksoy N, Yildiz H et al. Malondialdehyde in benign prostate hypertrophy: a useful marker? Mediators of Inflammation. 2003; 12 (2): 127-128. doi:10.1080/0962935031000097745
29. Oparinde DP, Atiba AS, Adegun PT, Adeola‘Niran-Atiba T. Serum Malondialdehyde, gamma glutamyl transferase and prostate specific antigen as markers of cancer of the prostate. International Journal of Biotechnology 2013; 2 (3): 59-67.
30. Ahmed NS, Shafik NM, Elraheem OA, Abou-Elnoeman SE. Association of paraoxonase-1(Q192R and L55M) gene polymorphisms and activity with colorectal cancer and effect of surgical intervention. Asian Pacific journal of Cancer Prevention. 2015; 16 (2): 803-809. doi:10.7314/ apjcp.2015.16.2.803
31. Korkmaz H, Tabur S, Ozkaya M, Aksoy N, Yildiz H et al. Paraoxonase and arylesterase activities in patients with papillary thyroid cancer. Scandinavian journal of clinical and Laboratory Investigation. 2015; 75 (3): 259-264. doi:10.3109/0 0365513.2014.1003597